Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, according to a new survey. Professional guidelines say that when pulmonary ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

Piper Sandler adjusted its outlook on Keros Therapeutics (NASDAQ:KROS), significantly reducing the price target from $40.00 ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...

2008;1(6):749-757. Current drugs available for the treatment of primary arterial hypertension (PAH) do not markedly improve survival and novel therapeutic strategies are required. Bone ...

A body weight-adjusted regimen of Uptravi dosing for children and adolescents with PAH was deemed appropriate, according to a ...

A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...